Sagimet Biosciences' license partner Ascletis reported positive 52-week results from a Phase 3 open-label extension trial of denifanstat, an oral acne drug. The trial showed significant and sustained improvements in moderate to severe acne, including a 57% success rate on Investigator’s Global Assessment and substantial lesion reductions. Denifanstat, a fatty acid synthase inhibitor, targets acne by reducing sebum production and inflammation. Sagimet is advancing denifanstat into a U.S. Phase 3 trial, with patient screening underway.
Sagimet Biosciences' license partner Ascletis reported positive 52-week Phase 3 trial results for denifanstat in acne, providing context for health sector performance. For readers following the health sector, here is Pluang's market snapshot as of Oct 09, 2026 17:11 WIB: of 128 priced US health stocks, 66 rose and 52 fell. Notably, TXG traded at USD 79.00 with a 1-day change of +2.23% and a typical hold time of 92 days, contrasting with ACB at USD 4.34, down 2.03% with a 25-day hold time, and CNC at USD 65.76, up 1.89% with a 42-day hold time.
ZenaTech introduced Stacklens™, AI-powered smart safety glasses designed for field technicians and industrial workers, integrating hands-free AI assistance, real-time video support, and thermal imaging. The glasses aim to improve efficiency by allowi...
A decade-old bug in the XRP Ledger's payment system could have allowed attackers to create and spend new XRP tokens without funding them, violating the fixed supply of 100 billion XRP. The vulnerability involved a counting error in the ledger's built...
Coinbase's spot Bitcoin order book revealed a significant sell order of 61.63 BTC valued at about $5.1 million, placed slightly above the market midpoint price of $82,523. Nearby sell orders total approximately $23.4 million, while buy orders are clo...
BlackRock's iShares Bitcoin Trust (IBIT), the largest US spot Bitcoin ETF, recorded a $22.38 million net inflow on October 9, 2026, following a significant $207.7 million outflow two days earlier. The fund holds actual Bitcoin through Coinbase Prime ...
U.S. spot Bitcoin ETFs recorded a net inflow of $21.1 million on October 9, reversing the previous day's $244.1 million outflow. BlackRock’s iShares Bitcoin Trust led with $22.4 million in inflows, while Fidelity’s Wise Origin Bitcoin Fund saw a $3.6...
